In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...
Read More
In a nutshell This study examined the effectiveness of a modified anti-nausea and vomiting treatment for patients with aggressive non-Hodgkin lymphoma (NHL) receiving high-dose (HD) chemotherapy. The results showed that netupitant/palonosetron (NEPA; Akynzeo) alone was very effective and safe for these patients. Some background Chemotherapy...
Read MoreIn a nutshell This article reviewed treatment options for patients with diffuse large B-cell lymphoma (DLBCL). The authors concluded that further advancements in therapies and technology would allow for more personalized treatment in the future. Some background About 30 – 40% of cases of NHL are diffuse large B-cell lymphoma (DLBCL)....
Read MoreIn a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read MoreIn a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read MoreIn a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...
Read MoreIn a nutshell This study evaluated the effectiveness of chemoimmunotherapy in children and adolescents with aggressive B-cell non-Hodgkin’s lymphoma (NHL). This study concluded that combined chemoimmunotherapy is highly effective in these young patients. Some background B-cell NHL is one of the most common types of lymphoma in children and...
Read MoreIn a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...
Read MoreIn a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...
Read MoreIn a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read MoreIn a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...
Read More
